. . . . . . . "[On the basis of its in vitro activity against FLT3 TKI-resistant F691 substitutions, further clinical evaluation of ponatinib in TKI-na�ve and select TKI-resistant FLT3-ITD+ AML patients is warranted.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en . . . . . "2017-02-19"^^ . . "Gene-disease associations inferred from text-mining the literature."@en . "DisGeNET evidence - LITERATURE"@en . "2017-10-17T13:12:47+02:00"^^ . . . . . . . . . . . "v5.0.0.0" . "v5.0.0" .